8 completed, 3 unknown, 1 recruiting, 1 terminated. 13 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 13 | Completed 8, Unknown 3, Recruiting 1, Terminated 1 |
Follow Language Disorders: new trials by email Literature Review of Language Disorders trials Research Report on Language Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of Motor Tasks and Lidocaine on Reading Unfamiliar Words in Adults With and Without Dyslexia Lidocaine 2% Polyampoule - Reading Disorders | Phase 4 | Completed | University of Alberta | 56 | 2023-08-24 | 2026-02-05 |
| Comparative Study Between Three Different Methods for Stuttering Therapy in Children speech therapy only, hyperbaric oxygen therapy, medical treatment - Stuttering, Childhood | Phase 4 | Unknown | Sohag University | 30 | 2022-04-01 | 2022-03-22 |
| Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech AV-1451 - PPA, Non-fluent Aphasia | Phase 4 | Recruiting | Mayo Clinic | 50 | 2018-07-01 | 2025-11-12 |
| Interventions for Children With Attention and Reading Disorders Methylphenidate, Intensive reading instruction, Parent Training - Attention Deficit Hyperactivity Disorder, Reading Disabilities | Phase 4 | Completed | The University of Texas Health Science Center, Houston | 222 | 2010-11-01 | 2017-04-11 |
| Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia Atomoxetine, Placebo - Attention Deficit Hyperactivity Disorder, Dyslexia | Phase 4 | Completed | Eli Lilly and Company | 110 | 2008-09-01 | 2022-11-04 |
| Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia Atomoxetine, Placebo - Attention Deficit Hyperactivity Disorder, Dyslexia | Phase 4 | Completed | Eli Lilly and Company | 209 | 2008-03-01 | 2011-12-15 |
| Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD) Atomoxetine Hydrochloride, placebo - Attention Deficit Hyperactivity Disorder, Reading Disorder | Phase 4 | Completed | Eli Lilly and Company | 121 | 2005-04-01 | 2010-05-25 |
| Memantine and Intensive Speech-Language Therapy in Aphasia memantine, constraint-induced language therapy (CIAT), placebo - Aphasia, Stroke | Phase 4 | Completed | Gabinete Berthier y Martínez | 28 | 2005-03-01 | 2008-03-21 |
| Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial memantine, constraint-induced language therapy - Aphasia, Stroke | Phase 4 | Unknown | Gabinete Berthier y Martínez | 30 | 2005-03-01 | 2005-09-20 |
| Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dyslexia Levodopa - Dyslexia | Phase 4 | Unknown | University Hospital Muenster | 100 | 2005-01-01 | 2014-12-05 |
| Dopaminergic Enhancement of Learning and Memory in Aphasia levodopa - Cerebrovascular Accident, Aphasia | Phase 4 | Completed | University Hospital Muenster | 12 | 2005-01-01 | 2013-10-07 |
| Donepezil in Chronic Poststroke Aphasia: a Randomized Controlled Trial Donepezil - Stroke, Aphasia | Phase 4 | Completed | Gabinete Berthier y Martínez | 30 | 2003-02-01 | 2005-09-20 |
| A Study to Evaluate the Efficacy and Safety of Piracetam on Aphasia After Acute Ischemic Cerebral Artery Stroke Piracetam, Placebo - Acute Ischaemic Middle Cerebral Artery Stroke | Phase 4 | Terminated | UCB S.A. - Pharma Sector | 571 | 1998-08-01 | 2013-08-30 |
Aphasia (6) · Dyslexia (6) · Stroke (5) · Attention Deficit Disorder with Hyperactivity (4) · Aphasia, Broca (1) · Aphasia, Primary Progressive (1) · Apraxias (1) · Ischemia (1) · Primary Progressive Nonfluent Aphasia (1) · Stuttering (1)
Communication Disorders (13) · Nervous System Diseases (13) · Neurobehavioral Manifestations (13) · Neurologic Manifestations (13) · Pathological Conditions, Signs and Symptoms (13) · Signs and Symptoms (13) · Mental Disorders (7) · Speech Disorders (7) · Brain Diseases (6) · Central Nervous System Diseases (6) · Learning Disabilities (6) · Neurodevelopmental Disorders (6) · Specific Learning Disorder (6) · Cardiovascular Diseases (5)
Atomoxetine Hydrochloride (4) · Levodopa (2) · Memantine (2) · 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (1) · Donepezil (1) · Guanfacine (1) · Hyperbaric Oxygenation (1) · Lidocaine (1) · Methylphenidate (1) · Piracetam (1)
Eli Lilly and Company (3) · Gabinete Berthier y Martínez (3) · University Hospital Muenster (2) · Mayo Clinic (1) · Sohag University (1) · The University of Texas Health Science Center, Houston (1) · UCB S.A. - Pharma Sector (1) · University of Alberta (1)
Spain (4) · United States (4) · Germany (3) · Belgium (2) · Argentina (1) · Austria (1) · Canada (1) · France (1) · Greece (1) · Hungary (1) · Italy (1) · Netherlands (1) · Norway (1) · Poland (1) · Singapore (1)
Marcelo L. Berthier, M.D., Ph.D (2) · Carolyn A Denton, Ph.D. (1) · Caterina Breitenstein, PhD (1) · Jennifer Whitwell, PhD (1) · Marcelo L. Berthier, M.D., Ph.D. (1) · Stefan Knecht, MD (1) · Stefan Knecht, Prof. Dr. (1)
PMID 25019647, PMID 20035588, PMID 24206099, PMID 25588456, PMID 27410907, PMID 27845858, PMID 33772416, PMID 42179727
2019 (1), R01DC012519 (1), R01HD060617 (1)